Market Newsdesk

Bruker Launches MyGenius PRO^® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026

MUNICH–(BUSINESS WIRE)–
At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO^®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius^®system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO^® automates the entire workflow – from patient sample to diagnostic result – enhancing laboratory efficiency and supporting higher-throughput volume testing needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417698008/en/

At launch, the MyGenius PRO^® IVDR menu will include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, are planned throughout 2026.

The MyGenius PRO^® platform was developed in a collaboration between ELITechGroup, a Bruker company, and Hitachi High Tech-Corporation (Hitachi High-Tech), combining complementary expertise in molecular assays, automation and engineering. Hitachi High-Tech will introduce the platform under the tradename LABOSPECT GA-5 in Japan. This system comes with Bruker molecular diagnostic assays for infectious disease testing in accordance with Japanese diagnostic regulations.

During a recent interview, Dr. Pierangelo Clerici, President of AMCLI (Italian Association of Clinical Microbiologists), emphasized the importance of high throughput in microbiology laboratories: “Timely diagnosis is critical in microbiology and virology. Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring, while enabling laboratories to streamline workflows and ensure compliance with IVDR regulations.”

The launch of MyGenius PRO^® marks a new chapter in Bruker’s Microbiology & Infection Diagnostics molecular diagnostics strategy, further expanding a portfolio that includes InGenius^®, BeGenius^®, a rapidly growing CE-IVD assay menu, and novel LiquidArray^® assays for advanced multiplexing and more affordable syndromic panel testing.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

About Hitachi High-Tech

Hitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Hitachi High-Tech also provide high value-added solutions in industrial fields such as mobility, environment and energy, etc.

For further information, visit https://www.hitachi-hightech.com/global/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417698008/en/

Trade Press & Customer Contact:

Alessandro Abramo

Director Marketing & Product Management

Bruker Microbiology & Infection Diagnostics Division

T: +39-348-360-9058

E: [email protected]

Investor Contact:

Joe Kostka

Director, Investor Relations & Corporate Development

Bruker Corporation

T: +1 (978) 313-5800

E: [email protected]

 

KEYWORDS: Germany Europe

INDUSTRY KEYWORDS: Technology Research Infectious Diseases Semiconductor Clinical Trials Biotechnology Health Pharmaceutical Science

MEDIA:

Photo

MyGenius PRO® installed at a leading European transplant center supporting routine infectious disease testing

Photo

The assays for CMV, EBV, and BKV launched with the MyGenius PRO® under IVDR

Logo

Regions Reports earnings of $539 million and EPS of $0.62 in 1Q 2026

$1.9 billion in total revenue reflects 5 percent year-over-year growth.

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
Regions Financial Corp. (NYSE:RF) today reported first quarter 2026 earnings of $539 million and diluted EPS of $0.62. Total revenue increased 5 percent, and pre-tax pre-provision income⁽¹⁾ increased 8 percent compared to first quarter of 2025. Adjusted total revenue⁽¹⁾ increased 4 percent, and adjusted pre-tax pre-provision income⁽¹⁾ increased 4 percent compared to first quarter of 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417465449/en/

Financial Highlights										Soundness
	Quarter Ended									Low-cost deposit base continued to deliver peer-leading interest-bearing deposit costs of 1.72% in 1Q26 Robust capital with CET1 of 10.6% (9.4% inclusive of AOCI(1)) supported by strong organic capital generation Business services criticized loans as a percent of business loans decreased 16 bps to 5.15% while NPLs to total loans decreased 2 bps to 0.71%; ACL/NPLs remains solid at 238%
($ amounts in millions, except per share data)		1Q26				4Q25
Earnings Summary
Net income	$	559			$	534
Net income available to common shareholders		539				514
Adj. net income avail. to common shareholders(1)		539				504
Diluted earnings per common share		0.62				0.58
Adj. diluted earnings per common share(1)		0.62				0.57				Profitability
Balance Sheet Summary										Best-in-class hedging program creates a mostly neutral short-term interest rate position and supports a top-quartile 1Q26 NIM of 3.67% Regions has consistently generated top-quartile returns vs its peer group; 1Q26 ROATCE of 18.26% Expenses remain well-controlled; supports self-funding of growth initiatives
Average loans	$	96,423			$	95,651
Average deposits		130,234				129,850
Credit Quality
Allowance for credit losses ratio		1.68	%			1.76	%
Net charge-offs / average loans*		0.54				0.59
Selected Ratios
Return on average assets*		1.42	%			1.34	%			Growth
Return on average common equity*		12.35				11.58				Net income grew 16% and diluted EPS 22% YoY; Adj. net income grew 11% and diluted EPS 15%(1) 1Q26 average loans increased 1% while ending loans increased 2% vs 4Q25; growth driven primarily by high-quality broad-based C&I loans 1Q26 reflects a record quarter of Treasury Management fees Significant progress in hiring and reskilling of bankers to support growth initiatives throughout the company’s priority markets
Return on avg. tangible common equity*(1)		18.26				17.17
Adj. return on avg. tangible common equity*(1)		18.26				16.84
Net interest margin (FTE)*		3.67				3.70
Efficiency ratio		56.6				56.8
Adjusted efficiency ratio(1)		56.6				57.5
Common equity Tier 1 ratio(2)		10.7				10.9
Common equity Tier 1 ratio (incl. AOCI)(1)(2)		9.4				9.7
Effective Tax Rate		21.6				24.5
*Annualized (1) Non-GAAP; refer to reconciliations in the financial supplement to this earnings release included as Exhibit 99.2 to the company’s Current Report on Form 8-K that was furnished to the SEC on Apr. 17, 2026. (2) Current quarter is estimated.

John Turner, Chairman, President and CEO of Regions Financial Corp.

“Our results reflect the strength of our franchise, the continued momentum of our markets, and our consistent focus on solid execution amid an evolving macroeconomic backdrop. Growth in loans and deposits accelerated during the first quarter, credit metrics continued to improve, and client sentiment remained generally optimistic across our footprint. At the same time, we are making meaningful progress on our core transformation, including key technology and AI investments that are enhancing efficiency and the customer experience, while remaining attentive to near‑term growth drivers. Together, these actions support our confidence to deliver on our strategic priorities throughout the year.”

Total revenue
		Quarter Ended
($ amounts in millions)		3/31/2026				12/31/2025				3/31/2025				1Q26 vs. 4Q25							1Q26 vs. 1Q25
Net interest income		$	1,248			$	1,281			$	1,194			$	(33	)		(2.6	)%		$	54			4.5	%
Taxable equivalent adjustment			13				13				12				—			—	%			1			8.3	%
Net interest income, taxable equivalent basis		$	1,261			$	1,294			$	1,206			$	(33	)		(2.6	)%		$	55			4.6	%
Net interest margin (FTE)*			3.67	%			3.70	%			3.52	%
Non-interest income:
Service charges on deposit accounts		$	163			$	163			$	161			$	—			—	%		$	2			1.2	%
Card and ATM fees			117				123				117				(6	)		(4.9	)%			—			—	%
Wealth management income			141				143				129				(2	)		(1.4	)%			12			9.3	%
Capital markets income			84				80				80				4			5.0	%			4			5.0	%
Mortgage income			32				32				40				—			—	%			(8	)		(20.0	)%
Commercial credit fee income			30				30				27				—			—	%			3			11.1	%
Bank-owned life insurance			30				23				23				7			30.4	%			7			30.4	%
Market value adjustments on employee benefit assets**			(5	)			(5	)			(3	)			—			NM				(2	)		66.7	%
Securities gains (losses), net			(3	)			—				(25	)			(3	)		NM				22			88.0	%
Other miscellaneous income			36				51				41				(15	)		(29.4	)%			(5	)		(12.2	)%
Non-interest income		$	625			$	640			$	590			$	(15	)		(2.3	)%		$	35			5.9	%
Adjusted non-interest income (non-GAAP)(1)		$	625			$	640			$	615			$	(15	)		(2.3	)%		$	10			1.6	%
Total revenue		$	1,873			$	1,921			$	1,784			$	(48	)		(2.5	)%		$	89			5.0	%
Adjusted total revenue (non-GAAP)(1)		$	1,873			$	1,921			$	1,809			$	(48	)		(2.5	)%		$	64			3.5	%
NM – Not Meaningful * Annualized ** These market value adjustments relate to assets held for employee and director benefits that are effectively offset within salaries and employee benefits and other non-interest expense.

While total revenue has increased versus the first quarter of 2025, it decreased 2 percent on both a reported and adjusted basis⁽¹⁾ compared to the fourth quarter of 2025. Net interest income decreased 3 percent driven primarily by fewer days in the quarter and elevated non-recurring items in the prior quarter that did not repeat. Total net interest margin was also negatively impacted by tighter asset spreads associated with higher-quality asset growth contributing to a 3 basis point decrease to 3.67 percent.

Non-interest income decreased 2 percent on both a reported and adjusted basis⁽¹⁾ during the first quarter. Capital markets increased 5 percent in the first quarter attributable to higher loan syndication and securities underwriting activity, as well as commercial swap income. Bank-owned life insurance increased 30 percent primarily due to higher claims income. Service charges, wealth management and mortgage income remained relatively stable compared to the fourth quarter of 2025. Card and ATM fees decreased 5 percent due primarily to seasonally lower activity. Other miscellaneous income also decreased during the quarter attributable primarily to commercial lease sales activity with $6 million of gains recognized in the prior quarter compared to $7 million of losses recognized in the current quarter.

Non-interest expense
		Quarter Ended
($ amounts in millions)		3/31/2026			12/31/2025			3/31/2025			1Q26 vs. 4Q25							1Q26 vs. 1Q25
Salaries and employee benefits		$	659		$	662		$	625		$	(3	)		(0.5	)%		$	34			5.4	%
Equipment and software expense			108			112			99			(4	)		(3.6	)%			9			9.1	%
Net occupancy expense			72			74			70			(2	)		(2.7	)%			2			2.9	%
Outside services			42			45			40			(3	)		(6.7	)%			2			5.0	%
Marketing			29			29			30			—			—	%			(1	)		(3.3	)%
Professional, legal and regulatory expenses			28			30			23			(2	)		(6.7	)%			5			21.7	%
Credit/checkcard expenses			14			18			15			(4	)		(22.2	)%			(1	)		(6.7	)%
FDIC insurance assessments			19			3			20			16			NM				(1	)		(5.0	)%
Visa class B shares expense			1			8			7			(7	)		(87.5	)%			(6	)		(85.7	)%
Operational losses			10			9			13			1			11.1	%			(3	)		(23.1	)%
Other miscellaneous expenses			86			108			97			(22	)		(20.4	)%			(11	)		(11.3	)%
Non-interest expense		$	1,068		$	1,098		$	1,039		$	(30	)		(2.7	)%		$	29			2.8	%
Adjusted non-interest expense (non-GAAP)(1)		$	1,068		$	1,112		$	1,035		$	(44	)		(4.0	)%		$	33			3.2	%

Salaries and Employee Benefits Expense
		Quarter Ended
($ amounts in millions)		3/31/2026				12/31/2025			3/31/2025				1Q26 vs. 4Q25							1Q26 vs. 1Q25
Salaries and employee benefits		$	659			$	662		$	625			$	(3	)		(0.5	)%		$	34			5.4	%
Less: Market value adjustments on supplemental 401(k) liabilities(*)			(4	)			6			(1	)			(10	)		(166.7	)%			(3	)		(300.0	)%
Salaries and employee benefits less market value adjustments on employee benefit liabilities		$	663			$	656		$	626			$	7			1.1	%		$	37			5.9	%
NM – Not Meaningful * The company holds assets in order to effectively offset the market value adjustments on supplemental 401(k) liabilities and the market value adjustments on those assets are recorded in non-interest income.

Non-interest expenses decreased 3 percent on a reported basis and 4 percent on an adjusted basis⁽¹⁾ compared to the fourth quarter of 2025, reflecting broad-based improvement across most expense categories. Salaries and benefits remained relatively stable as declines in market value adjustments for supplemental employee benefit liabilities offset the seasonal increases in payroll taxes, 401(k) contributions, and one month of merit. FDIC insurance assessments increased $16 million attributable to an adjustment for the company’s FDIC special insurance assessment recognized in the prior quarter. The company’s first quarter efficiency ratio was 56.6 percent on both a reported and adjusted basis⁽¹⁾.

Loans
		Average Balances
($ amounts in millions)			1Q26			4Q25			1Q25		1Q26 vs. 4Q25							1Q26 vs. 1Q25
Commercial and industrial		$	49,572		$	48,769		$	49,209		$	803			1.6	%		$	363			0.7	%
Commercial real estate—owner-occupied			5,146			5,126			5,180			20			0.4	%			(34	)		(0.7	)%
Investor real estate			9,327			9,116			8,751			211			2.3	%			576			6.6	%
Business Lending			64,045			63,011			63,140			1,034			1.6	%			905			1.4	%
Residential first mortgage			19,674			19,822			20,037			(148	)		(0.7	)%			(363	)		(1.8	)%
Home equity			5,514			5,546			5,509			(32	)		(0.6	)%			5			0.1	%
Consumer credit card			1,473			1,458			1,394			15			1.0	%			79			5.7	%
Other consumer*			5,717			5,814			6,042			(97	)		(1.7	)%			(325	)		(5.4	)%
Consumer Lending			32,378			32,640			32,982			(262	)		(0.8	)%			(604	)		(1.8	)%
Total Loans		$	96,423		$	95,651		$	96,122		$	772			0.8	%		$	301			0.3	%

		Ending Balances
											3/31/2026							3/31/2026
($ amounts in millions)		3/31/2026			12/31/2025			3/31/2025			vs. 12/31/2025							vs. 3/31/2025
Commercial and industrial		$	50,824		$	48,790		$	48,879		$	2,034			4.2	%		$	1,945			4.0	%
Commercial real estate—owner-occupied			5,265			5,108			5,165			157			3.1	%			100			1.9	%
Investor real estate			9,644			9,106			8,833			538			5.9	%			811			9.2	%
Business Lending			65,733			63,004			62,877			2,729			4.3	%			2,856			4.5	%
Residential first mortgage			19,621			19,765			20,000			(144	)		(0.7	)%			(379	)		(1.9	)%
Home equity			5,497			5,556			5,501			(59	)		(1.1	)%			(4	)		(0.1	)%
Consumer credit card			1,472			1,519			1,384			(47	)		(3.1	)%			88			6.4	%
Other consumer*			5,603			5,793			5,971			(190	)		(3.3	)%			(368	)		(6.2	)%
Consumer Lending			32,193			32,633			32,856			(440	)		(1.3	)%			(663	)		(2.0	)%
Total Loans		$	97,926		$	95,637		$	95,733		$	2,289			2.4	%		$	2,193			2.3	%
NM – Not meaningful. * Other consumer loans includes Regions’ Home Improvement Financing portfolio.

Average loans increased 1 percent while ending loans increased 2 percent compared to the prior quarter. Average business loans increased 2 percent during the quarter while average consumer loans decreased 1 percent. Growth was driven by broad-based C&I lending including power and utilities, manufacturing, healthcare and asset-based lending. Approximately half of this quarter’s growth came from higher line utilization, with the remainder of the balance driven by new loans, primarily with existing clients. Loan growth was also very high quality as almost two-thirds were investment grade credits and the majority of the remaining were near investment grade credits.

Deposits
		Average Balances
($ amounts in millions)			1Q26			4Q25			1Q25		1Q26 vs. 4Q25							1Q26 vs. 1Q25
Total interest-bearing deposits		$	91,074		$	90,391		$	88,634		$	683			0.8	%		$	2,440			2.8	%
Non-interest-bearing deposits			39,160			39,459			39,053			(299	)		(0.8	)%			107			0.3	%
Total Deposits		$	130,234		$	129,850		$	127,687		$	384			0.3	%		$	2,547			2.0	%
($ amounts in millions)			1Q26			4Q25			1Q25		1Q26 vs. 4Q25							1Q26 vs. 1Q25
Consumer Bank Segment		$	79,599		$	79,437		$	78,712		$	162			0.2	%		$	887			1.1	%
Corporate Bank Segment			40,707			40,243			38,312			464			1.2	%			2,395			6.3	%
Wealth Management Segment			7,777			7,810			7,600			(33	)		(0.4	)%			177			2.3	%
Other*			2,151			2,360			3,063			(209	)		(8.9	)%			(912	)		(29.8	)%
Total Deposits		$	130,234		$	129,850		$	127,687		$	384			0.3	%		$	2,547			2.0	%

		End of Period Deposits
											3/31/2026							3/31/2026
($ amounts in millions)		3/31/2026			12/31/2025			3/31/2025			vs. 12/31/2025							vs. 3/31/2025
Consumer Bank Segment		$	81,271		$	80,193		$	80,627		$	1,078			1.3	%		$	644			0.8	%
Corporate Bank Segment			40,574			40,449			39,696			125			0.3	%			878			2.2	%
Wealth Management Segment			7,750			8,344			7,798			(594	)		(7.1	)%			(48	)		(0.6	)%
Other*			2,285			2,142			2,850			143			6.7	%			(565	)		(19.8	)%
Total Deposits		$	131,880		$	131,128		$	130,971		$	752			0.6	%		$	909			0.7	%
NM – Not meaningful. *Other deposits represent non-customer balances primarily consisting of wholesale funding (for example, selected deposits and brokered time deposits) and additional wholesale funding arrangements.

The company’s deposit base continues to be a source of strength and an industry differentiator in liquidity and margin performance. Ending deposits increased approximately 1 percent while average deposits increased modestly during the quarter. Average corporate deposits increased 1 percent, while average consumer and wealth deposits remained relatively stable. Ending consumer deposits increased over 1 percent reflecting typical seasonal patterns associated primarily with income tax refunds, as well as the focus on customer acquisition and priority markets.

Asset quality
		As of and for the Quarter Ended
($ amounts in millions)		3/31/2026		12/31/2025		3/31/2025
Allowance for credit losses (ACL) at period end		$1,647		$1,686		$1,730
ACL/Loans, net		1.68%		1.76%		1.81%
Business criticized loans to total business loans		5.15%		5.31%		7.82%
Allowance for credit losses to non-performing loans, excluding loans held for sale		238%		242%		205%
Provision for credit losses		$91		$115		$124
Net loans charged-off		$130		$142		$123
Net loans charged-off as a % of average loans, annualized		0.54%		0.59%		0.52%
Non-performing loans, excluding loans held for sale/Loans, net		0.71%		0.73%		0.88%
NPAs (ex. 90+ past due)/Loans, foreclosed properties, and non-performing loans held for sale		0.73%		0.75%		0.92%
NPAs (inc. 90+ past due)/Loans, foreclosed properties, and non-performing loans held for sale*		0.90%		0.94%		1.11%
Total Criticized Loans—Business Services**		$3,384		$3,342		$4,918
* Excludes fully guaranteed residential first mortgages that are 90+ days past due and still accruing. ** Business services represents the combined total of commercial and investor real estate loans.

Overall asset quality continues to demonstrate improvement. Based on recent discussions with commercial clients and ongoing relationship-manager engagement, customer sentiment remains generally optimistic, and consumer fundamentals continue to be sound. Aggregate spending trends among Regions’ consumer customers are stable to modestly positive, and labor market conditions show no indications of material weakness.

Net charge-offs were $130 million or an annualized 54 basis points of average loans, representing a 5 basis point decrease compared to the fourth quarter of 2025. The majority of business services charge-offs came from previously identified portfolios of interest with established reserves. Business services criticized loans and non-performing loans remained relatively stable with the ratio of non-performing loans as a percentage of total loans declining 2 basis points to 0.71 percent and the ratio of business services criticized loans as a percentage of total business loans declining 16 basis points to 5.15 percent.

Allowance increases tied to loan growth and greater macroeconomic uncertainty were more than offset by meaningful progress in resolving loans within previously identified portfolios of interest, sustained risk-rating upgrades exceeding downgrades, and continued improvement in business services criticized and total non-performing loan ratios. As a result, the allowance for credit losses declined $39 million. Strengthening asset quality across portfolios, combined with high-quality loan growth, drove an 8 basis point reduction in the allowance ratio to 1.68 percent, while coverage of non-performing loans remained solid at 238 percent.

Capital and liquidity
		As of and for Quarter Ended
		3/31/2026		12/31/2025		3/31/2025
Common Equity Tier 1 ratio(2)		10.7%		10.9%		10.8%
Common equity Tier 1 ratio (incl. AOCI) (non-GAAP)(1)(2)		9.4%		9.7%		9.1%
Tier 1 capital ratio(2)		11.7%		12.0%		12.2%
Total shareholders’ equity to total assets		11.68%		11.99%		11.59%
Tangible common shareholders’ equity to tangible assets (non-GAAP)(1)		7.54%		7.80%		7.17%
Common book value per share		$20.39		$20.36		$18.70
Tangible common book value per share (non-GAAP)(1)		$13.69		$13.75		$12.29
Loans, net of unearned income, to total deposits		74.3%		72.9%		73.1%

Regions maintained a solid capital position in the first quarter with estimated capital ratios remaining well above current regulatory requirements. At quarter-end, the Common Equity Tier 1 (CET1)⁽²⁾ and Tier 1 capital⁽²⁾ ratios were estimated at 10.7 percent and 11.7 percent respectively. Including the impacts of accumulated other comprehensive income, CET1⁽¹⁾⁽²⁾ was estimated at 9.4 percent.

During the first quarter, the company repurchased approximately 14 million shares of common stock for a total of $401 million through open-market purchases and declared $227 million in dividends to common shareholders.

Tangible common book value per share⁽¹⁾ ended the quarter at $13.69, an 11 percent increase year-over-year.

The company’s liquidity position also remained robust with total available liquidity as of March 31, 2026, of approximately $68 billion, which includes cash held at the Federal Reserve, FHLB borrowing capacity, unencumbered securities, and capacity at the Federal Reserve’s facilities such as the Discount Window or Standing Repo Operations. These sources are sufficient to cover uninsured deposits at a ratio of approximately 178 percent as of quarter-end (excluding intercompany and secured deposits).

(1) Non-GAAP; refer to reconciliations on pages 11, 14, 15 and 16 of the financial supplement to this earnings release included as Exhibit 99.2 to the company’s Current Report on Form 8-K that was furnished to the Securities and Exchange Commission on Apr. 17, 2026.

(2) Current quarter Common Equity Tier 1 and Tier 1 capital ratios are estimated.

Conference Call

The company will hold a live audio webcast to discuss first quarter 2026 results on April 17, 2026 at 10 a.m. ET. To access this live audio webcast, visit the Investor Relations page at ir.regions.com. An archived recording of the webcast will be available at the Investor Relations page at ir.regions.com following the live event.

About Regions Financial Corporation

Regions Financial Corporation (NYSE:RF), with $161 billion in assets, is a member of the S&P 500 Index and is one of the nation’s largest full-service providers of consumer and commercial banking, wealth management, and mortgage products and services. Regions serves customers across the South, Midwest and Texas, and through its subsidiary, Regions Bank, operates more than 1,200 banking offices and more than 1,750 ATMs. Regions Bank is an Equal Housing Lender and Member FDIC. Additional information about Regions and its full line of products and services can be found at www.regions.com.

Forward-Looking Statements

This release and the accompanying earnings call may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. In addition, the company, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. The words “future,” “anticipates,” “assumes,” “intends,” “plans,” “seeks,” “believes,” “predicts,” “potential,” “objectives,” “estimates,” “expects,” “targets,” “projects,” “outlook,” “forecast,” “would,” “will,” “may,” “might,” “could,” “should,” “can,” and similar terms, expressions, and graphics often signify forward-looking statements. Forward-looking statements are subject to the risk that the actual effects may differ, possibly materially, from what is reflected in those forward-looking statements due to factors and future developments that are uncertain, unpredictable and in many cases beyond our control. Forward-looking statements are not based on historical information, but rather are related to future operations, strategies, financial results or other developments. Forward-looking statements are based on management’s current expectations as well as certain assumptions and estimates made by, and information available to, management at the time the statements are made. Those statements are based on general assumptions and are subject to various risks, and because they also relate to the future, they are likewise subject to inherent uncertainties and other factors that may cause actual results to differ materially from the views, beliefs and projections expressed in such statements. Therefore, we caution you against relying on any of these forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, those described below:

• Our businesses have been, and may continue to be, adversely affected by conditions in the financial markets and economic conditions generally.

• Fluctuations in market interest rates, including the level and shape of the yield curve, may adversely affect our performance.

• If we experience greater credit losses in our loan portfolios than anticipated, our earnings may be materially adversely affected.

• Any future reductions in our credit ratings may increase our funding costs and place limitations on business activities.

• Changes in the soundness of other financial institutions could adversely affect us.

• We may suffer losses if the value of collateral declines in stressed market conditions.

• Ineffective liquidity management could adversely affect our financial results and condition.

• Loss of deposits or a change in deposit mix could increase our funding costs.

• We rely on the mortgage secondary market to manage various risks.

• We are at risk of a variety of systems failures or errors and cyber-attacks or other similar incidents that could adversely affect customer experience and our business and financial performance.

• We are subject to complex and evolving laws, regulations, rules, standards and contractual obligations regarding privacy and cybersecurity, which could increase the cost of doing business, compliance risks and potential liability.

• We will continually encounter technological change and must effectively anticipate, develop and implement new technology.

• The development and use of AI presents risks and challenges that may adversely impact our business.

• Industry competition, including competition from decentralized finance platforms, cryptocurrencies and blockchain technologies could disrupt our business model and adversely affect our revenues, market share or liquidity.

• Our operations are concentrated primarily in the South, Midwest and Texas, and adverse changes in the economic conditions in this region can adversely affect our financial results and condition.

• Weakness in the residential real estate markets could adversely affect our performance.

• Weakness in the commercial real estate markets could adversely affect our performance.

• Risks associated with home equity products where we are in a second lien position could adversely affect our performance.

• Weakness in commodity businesses could adversely affect our performance.

• An outbreak or escalation of hostilities between countries or within a country or region could have a material adverse effect on the U.S. economy and on our businesses.

• We are subject to a variety of operational risks, including the risk of fraud or theft by internal or external parties, which may adversely affect our business and results of operations.

• We rely on other companies to provide key components of our business infrastructure.

• We depend on the accuracy and completeness of information about clients and counterparties.

• We are exposed to risk of environmental liability when we take title to property.

• We can be negatively affected if we fail to identify and address operational risks associated with the introduction of or changes to products, services and delivery platforms.

• Enhanced regulatory and other standards for the oversight of vendors and other service providers can result in higher costs and other potential exposures.

• We are, and may in the future be, subject to claims and litigation calling into question our right to use the intellectual property underlying certain technology in our business.

• Weather-related events, pandemics and other natural or man-made disasters could cause a disruption in our operations or lead to other consequences that could adversely impact our financial results and condition. These impacts could be intensified by climate change. Heightening focus on climate change may also carry transition risks that could negatively impact our results of operations and financial condition.

• We are subject to sociopolitical risks that could adversely affect our business, reputation and the trading price of our common stock.

• Damage to our reputation could significantly harm our businesses.

• We are, and may in the future be, subject to litigation, investigations and governmental proceedings that may result in liabilities adversely affecting our financial condition, business or results of operations or in reputational harm.

• We are subject to extensive governmental regulation, which could have an adverse impact on our operations and our business model.

• We are subject to a variety of risks in connection with any sale of loans we may conduct.

• We may be subject to more stringent capital and liquidity requirements.

• Rulemaking changes and regulatory initiatives implemented by the CFPB may result in higher regulatory and compliance costs that may adversely affect our results of operations.

• We are subject to numerous laws designed to protect consumers, including the CRA and fair lending laws, and a failure to comply with these laws could lead to a wide variety of penalties and other sanctions.

• We may not be able to complete future acquisitions, may not be successful in realizing the benefits of any future acquisitions that are completed or may choose not to pursue acquisition opportunities we might find beneficial.

• Increases in FDIC insurance assessments may adversely affect our earnings.

• Unfavorable results from ongoing stress analyses may adversely affect our ability to retain customers or compete for new business opportunities.

• We are a holding company and depend on our subsidiaries for dividends, distributions and other payments.

• We may not pay dividends on shares of our capital stock.

• Anti-takeover and banking laws and certain agreements and charter provisions may adversely affect share value.

• Our amended and restated by-laws designate (i) the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders and (ii) the federal district courts of the United States as the sole and exclusive forum for any action asserting a cause of action arising under the Securities Act, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with our company or our company’s directors, officers or other employees.

• We face substantial legal and operational risks in our safeguarding and other processing of personal information.

• Differences in regulation can affect our ability to compete effectively.

• Our businesses may be adversely affected if we are unable to hire and retain qualified employees.

• Our operations rely on our ability, and the ability of key external parties, to maintain appropriately staffed workforces, and on the competence, trustworthiness, health and safety of employees.

• Our reported financial results depend on management’s selection of accounting methods and certain assumptions and estimates.

• If the models that we use in our business perform poorly or provide inadequate information, our business or results of operations may be adversely affected.

• Changes in our accounting policies or in accounting standards could materially affect how we report our financial results and condition.

The foregoing list of factors is not exhaustive. For discussion of these and other factors that may cause actual results to differ from expectations, look under the captions “Forward-Looking Statements” and “Risk Factors” in Regions’ Annual Report on Form 10-K for the year ended December 31, 2025 and in Regions’ subsequent filings with the SEC.

You should not place undue reliance on any forward-looking statements, which speak only as of the date made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible to predict all of them. We assume no obligation and do not intend to update or revise any forward-looking statements that are made from time to time, either as a result of future developments, new information or otherwise, except as may be required by law.

Use of Non-GAAP Financial Measures

Management uses pre-tax pre-provision income (non-GAAP), adjusted pre-tax pre-provision income (non-GAAP), the adjusted efficiency ratio (non-GAAP), the adjusted fee income ratio (non-GAAP), return on average tangible common shareholders’ equity (non-GAAP), adjusted return on average tangible common shareholders’ equity (non-GAAP), common equity Tier 1 ratio (inclusive of AOCI) (non-GAAP), as well as adjusted net income available to common shareholders (non-GAAP) and adjusted diluted EPS (non-GAAP) to monitor performance and believes these measures provide meaningful information to investors. Non-interest expense (GAAP) is presented excluding certain adjustments to arrive at adjusted non-interest expense (non-GAAP), which is the numerator for the adjusted efficiency ratio. Non-interest income (GAAP) is presented excluding certain adjustments to arrive at adjusted non-interest income (non-GAAP), which is the numerator for the adjusted fee income ratio. Adjusted non-interest income (non-GAAP) and adjusted non-interest expense (non-GAAP) are used to determine adjusted pre-tax pre-provision income (non-GAAP). Net interest income (GAAP) on a taxable-equivalent basis and non-interest income are added together to arrive at total revenue on a taxable-equivalent basis. Adjustments are made to arrive at adjusted total revenue on a taxable-equivalent basis (non-GAAP), which is the denominator for the adjusted fee income and adjusted efficiency ratios. Net income available to common shareholders (GAAP) is presented excluding certain adjustments, net of tax, to arrive at adjusted net income available to common shareholders (non-GAAP), which is the numerator for adjusted diluted EPS (non-GAAP). Return on average tangible common shareholders’ equity (non-GAAP) is calculated by dividing net income available to common shareholders (GAAP) by the average tangible common shareholders’ equity (non-GAAP). Net income available to common shareholders (GAAP) is presented excluding certain adjustments, net of tax, to arrive at adjusted net income available to common shareholders (non-GAAP), which is the numerator for adjusted return on average tangible common shareholders’ equity. Adjusted return on average tangible common shareholders’ equity is calculated by dividing the adjusted net income available to common shareholders (non-GAAP) by the average tangible common shareholders’ equity (non-GAAP). Adjusted common equity Tier 1 ratio (non-GAAP) is calculated by dividing the adjusted common equity tier 1 (non-GAAP), which is arrived at by excluding the AOCI loss on securities and AOCI loss on defined benefit pension plans and other post employment benefits from common equity Tier 1, by the company’s total risk-weighted assets (GAAP).

Regions believes that the exclusion of these adjustments provides a meaningful basis for period-to-period comparisons, which management believes will assist investors in analyzing the operating results of the company and predicting future performance. These non-GAAP financial measures are also used by management to assess the performance of Regions’ business. It is possible that the activities related to the adjustments may recur; however, management does not consider the activities related to the adjustments to be indications of ongoing operations. Regions believes that presentation of these non-GAAP financial measures will permit investors to assess the performance of the company on the same basis as that applied by management. Tangible common book value per share is calculated by dividing tangible common shareholders’ equity (non-GAAP) by tangible assets (non-GAAP). The numerator for tangible book value per share (non-GAAP), tangible common shareholders’ equity (non-GAAP), is calculated by excluding intangible assets and the deferred tax liability related to intangible assets from common shareholders’ equity (GAAP). The denominator for tangible book value per share (non-GAAP), tangible assets (non-GAAP), is calculated by excluding intangible assets and the deferred tax liability related to intangible assets from total assets (non-GAAP).

Tangible common shareholders’ equity ratios have become a focus of some investors and management believes they may assist investors in analyzing the capital position of the company absent the effects of intangible assets and preferred stock. Analysts and banking regulators have assessed Regions’ capital adequacy using the tangible common shareholders’ equity measure. Because tangible common shareholders’ equity is not formally defined by GAAP or prescribed in any amount by federal banking regulations it is currently considered to be a non-GAAP financial measure and other entities may calculate it differently than Regions’ disclosed calculations. Since analysts and banking regulators may assess Regions’ capital adequacy using tangible common shareholders’ equity to tangible assets, management believes that it is useful to provide investors the ability to assess Regions’ capital adequacy on this same basis.

Non-GAAP financial measures have inherent limitations, are not required to be uniformly applied and are not audited. Although these non-GAAP financial measures are frequently used by stakeholders in the evaluation of a company, they have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analyses of results as reported under GAAP. In particular, a measure of earnings that excludes selected items does not represent the amount that effectively accrues directly to stockholders. Additionally, our non-GAAP financial measures may not be comparable to similar non-GAAP financial measures used by other companies and there is no certainty that we will not incur expenses in the future that are similar to those excluded in the calculations of non-GAAP financial measures presented herein.

Management and the Board of Directors utilize non-GAAP measures as follows:

• Preparation of Regions’ operating budgets

• Monthly financial performance reporting

• Monthly close-out reporting of consolidated results (management only)

• Presentation to investors of company performance

• Metrics for incentive compensation

See the company’s Financial Supplement, included as Exhibit 99.2 to the company’s Current Report on Form 8-K furnished to the Securities and Exchange Commission on April 17, 2026, for reconciliations of and additional information regarding the company’s non-GAAP financial measures.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417465449/en/

Jeremy King

[email protected]

205.264.4895

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

Bruker Expands Industry-Leading MALDI Biotyper^® and IR Biotyper^® Workflows for Microbial Identification and Outbreak Management

• MALDI Biotyper^® (MBT): Launch of proprietary MBT Easy T^® Kit for consistent sample transfer to MALDI target plates
• MALDI Biotyper^®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria
• MALDI Biotyper^®: Early KOL access to a novel cloud‑based identification solution, enabling identification against several specialist, expert‑curated libraries
• MALDI Biotyper^®: Ongoing broad, multi‑year clinical and translational study programs advancing automation, potential future claims, and next‑generation analytics, including:
  • IVDR-compliant clinical validation studies evaluating automated sample preparation workflows, covering both colony‑based cultures (MBT PrepMatic™) and positive blood cultures (MBT SepsiMatic^®)
  • U.S. clinical studies intended to support upcoming identification claims for mycobacteria and filamentous fungi, with FDA submission targeted for 2026
  • Ongoing clinical evaluation of MBT FAST, a rapid phenotypic antimicrobial susceptibility testing approach, aiming to enable IVDR-compliant same‑day results from positive blood cultures and agar colonies for Enterobacteriaceae
  • Exploratory, data‑driven research studies presented at ESCMID, including AI‑based antibiotic resistance prediction for Staphylococcus aureus, derived from large MALDI Biotyper spectral datasets
• IR Biotyper^®: Enhanced outbreak detection with IR Tracker for surveillance of hospital‑acquired infections (HAIs) and new classifiers for Salmonella Typhi, STEC, and Shigella sp. detection
• MBioSEQ™ Ridom Typer: New software version, including TB‑Profiler antimicrobial resistance (AMR) determination, and GAMBIT bacterial species identification supporting MALDI / IR Biotyper^®-triggered WGS reflex testing workflows,with result application performed under laboratory responsibility
• Introduction of Molzym as a part of Bruker Microbiology and Infection Diagnostics

MUNICH–(BUSINESS WIRE)–
At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417265432/en/

MALDI Biotyper^® Workflow and Identification Enhancements

To further streamline routine MALDI‑TOF workflows, Bruker introduces the proprietary MBT Easy T^® Kit (RUO and IVDR), a consumables kit designed to simplify and standardize sample transfer steps to MALDI target plates. The kit includes ready-to-use reagents and applicators, supporting up to 2,000 samples, while enabling room temperature storage and reducing chemical waste.

In parallel, Bruker expands its MALDI Biotyper^® reference libraries to more than 5,300 species, including bacteria, yeasts, filamentous fungi, and mycobacteria (RUO). The latest library updates add more than 600 new species and significantly strengthen species coverage, particularly for the dedicated filamentous fungi MyT workflow which benefits from ~30% stronger species coverage. Corresponding IVDR‑registered library expansions are currently in progress.

To extend access to specialized identification content beyond local installations, Bruker is offering early access to a cloud‑based MALDI identification solution (RUO) for selected key opinion leaders and expert laboratories. This approach enables research use identification using specialist libraries curated by domain experts, within the MBT Compass HT environment. Initial expert libraries include yeast collections, anaerobic bacteria libraries developed by academic partners, and mosquito libraries supporting malaria vector monitoring and research. The cloud infrastructure allows visibility of library provenance and provides a foundation for future capabilities such as exclusive libraries, online system monitoring, and software updates.

Bruker continues to advance automation across sample preparation workflows with MBT PrepMatic™ and MBT SepsiMatic^® systems, both currently under evaluation in IVDR-compliant clinical validation studies. MBT PrepMatic™ is designed to enable semi‑ to fully automated colony picking from Petri dish cultures and preparation of MALDI target plates. MBT SepsiMatic^® is designed to support a fully automated workflow from positive blood culture bottles to prepared MALDI target plates, with the potential to produce purified samples containing viable cells for downstream analysis.

Advanced Clinical and Research Applications

Bruker is progressing multiple advanced applications for MALDI‑based microbiology. In the United States, clinical studies are underway to support upcoming claims for mycobacteria and filamentous fungi identification, with FDA submissions planned for 2026.

Clinical validation studies are underway on rapid phenotypic antimicrobial susceptibility testing (AST) using MALDI‑TOF MS, aimed at enabling same‑day results from positive blood cultures and agar colonies for Enterobacteriaceae. This approach explores the use of machine‑learning‑based growth assessment and aligns conceptually with CLSI‑ and EUCAST‑guided broth microdilution principles.

At ESCMID Global 2026, Bruker is also presenting poster data from exploratory research on AI‑driven antibiotic resistance prediction for Staphylococcus aureus, with AUROC >0.8, based on more than 2,600 MALDI Biotyper^® spectra (RUO). Further studies with expanded scope are ongoing.

Hospital Hygiene and Outbreak Management

In the area of hospital hygiene and epidemiology, Bruker expands IR Biotyper^® applications (GP) with IR Tracker for surveillance of hospital‑acquired infections (HAIs) and new classifiers for clinically and epidemiologically significant organisms. Newly supported targets include Salmonella Typhi, Shiga toxin‑producing E. coli (STEC), and Shigella species – pathogens associated with specific treatment requirements, high infectivity, and public health reporting obligations. These enhancements support rapid differentiation and classification to aid outbreak detection and infection control efforts.

Reflex NGS and Culture‑Independent Diagnostics

Bruker introduces a new software version of its MBioSEQ™ Ridom Typer (RUO), featuring short and long read whole genome sequencing (WGS) data analysis for research and expert laboratory applications. The software now includes TB-Profiler-based antimicrobial resistance (AMR) determination and GAMBIT bacterial species identification, supporting MALDI / IR Biotyper^®-triggered WGS reflex workflows as part of laboratory‑defined analysis processes.

In addition, Bruker announces the integration of Molzym following its acquisition in late 2025, further strengthening the company’s Microbiology & Infection Diagnostics portfolio. Molzym brings expertise in culture‑independent pathogen diagnostics, including its unique and patented MolYsis™ host‑DNA depletion technology, which selectively removes host DNA to enable highly sensitive detection of microbial DNA in low‑biomass and blood samples for subsequent sequencing analysis.

“In routine MALDI‑TOF identification, having critical reagents readily available in a standardized format is essential,” said Kirsten Schönfeld, Diplom-Biologin, Institut Dr. Nowak GmbH, Germany. “The MBT Easy T^® Kit provides pre‑filled, ready‑to‑use solvent ampoules, including formic acid, which will simplify logistics and daily laboratory operations. This helps maintain a robust and streamlined MALDI Biotyper workflow in a clinical setting.”

Dr. Wolfgang Pusch, President of Bruker’s Microbiology & Infection Diagnostics Division, added: “Feedback like this underscores why we continue to invest in practical innovations that strengthen everyday laboratory workflows. Across microbial identification and outbreak analysis, Bruker is pursuing a broad and sustained innovation initiative – significantly expanding our reference libraries, introducing new sample preparation options to enable the highest level of standardization, and advancing exploratory artificial‑intelligence‑based approaches for antibiotic resistance prediction from MALDI spectra. In parallel, we are driving the development of automation for sample preparation from both colonies and positive blood cultures, initiating clinical studies for MALDI Biotyper^®‑based rapid antimicrobial susceptibility testing, and further expanding the analytical capabilities of the IR Biotyper^®. At the same time, we continue to refine our NGS‑based MBioSEQ™ Ridom Typer , including ongoing, research‑use‑focused enhancements for tuberculosis antimicrobial resistance profiling.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417265432/en/

Trade Press & Customer Contact:

Alessandro Abramo

Director Marketing & Product Management

Bruker Microbiology & Infection Diagnostics Division

T: +39-348-360-9058

E: [email protected]

Investor Contact:

Joe Kostka

Director, Investor Relations & Corporate Development

Bruker Corporation

T: +1 (978) 313-5800

E: [email protected]

 

KEYWORDS: Germany Europe

INDUSTRY KEYWORDS: Biotechnology Technology Health Pharmaceutical Semiconductor Health Technology Research Infectious Diseases Software Science Clinical Trials

MEDIA:

Photo

MBT Easy T® Kit – Bruker’s consumables kit providing ready‑to‑use solvents and sample applicators for streamlined sample preparation in MALDI Biotyper®‑based microbial identification

Logo

CoStar Data Shows Aire Park Driving New Rental Highs in Leeds

LONDON–(BUSINESS WIRE)–
Leeds office demand shifts south of the river to the East Quarter, according to data from CoStar, a global leading provider of online real estate marketplaces, information and analytics in the property markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417361617/en/

While the traditional City Core remained Leeds’s dominant office location, its share of headline leasing activity fell from a five-year average of around 80% to 60% in 2025.

“A growing number of professional and financial services firms have been drawn to the East Quarter’s Aire Park for its new-build specifications, strong ESG credentials and proximity to the city centre,” said Giles Tebbitts, director of market analytics at CoStar Europe. “As the scheme matures, it has attracted an expanding roster of high-profile occupiers.”

Despite East Quarter accounting for more than 30% of leasing activity across the Leeds Central Business District (CBD) in 2025, most transactions were mid-sized lettings at Aire Park. The City Core continued to dominate smaller deals below 15,000 sq. ft., representing 81% of CBD activity.

“The CBD vacancy rate has been broadly stable at around 12% over the past three years, but up from a cyclical low of 6% in 2020,” said Tebbitts. “The withdrawal of older, obsolete stock has offset limited completions at Aire Park, keeping net absorption relatively flat in recent quarters.”

The full analysis can be found here.

For more information about the company and its products and services, please visit www.costargroup.com.

About CoStar Group

CoStar Group (NASDAQ: CSGP) is a global leader in commercial real estate information, analytics, online marketplaces, and 3D digital twin technology. Founded in 1986, CoStar Group is dedicated to digitizing the world’s real estate, empowering all people to discover properties, insights, and connections that improve their businesses and lives.

CoStar Group’s major brands include CoStar, a leading global provider of commercial real estate data, analytics, and news; LoopNet, the most trafficked commercial real estate marketplace; Apartments.com, the leading platform for apartment rentals; Homes.com, the fastest-growing residential real estate marketplace; and Domain, one of Australia’s leading property marketplaces. CoStar Group’s industry-leading brands also include Matterport, a leading spatial data company whose platform turns buildings into data to make every space more valuable and accessible; STR, a global leader in hospitality data and benchmarking; Ten-X, an online platform for commercial real estate auctions and negotiated bids; and OnTheMarket, a leading residential property portal in the United Kingdom.

CoStar Group’s websites attracted over 143 million average monthly unique visitors in the third quarter of 2025, serving clients around the world. Headquartered in Arlington, Virginia, CoStar Group is committed to transforming the real estate industry through innovative technology and comprehensive market intelligence. From time to time, we plan to utilize our corporate website as a channel of distribution for material company information. For more information, visit CoStarGroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417361617/en/

Media Contact

Karolina Capova

Senior Media Relations Specialist

[email protected]

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Professional Services Business Data Analytics Other Construction & Property Commercial Building & Real Estate Construction & Property

MEDIA:

Photo

CoStar Data Shows Aire Park Driving New Rental Highs in Leeds

Logo